The Financial Express1d
USFDA approves novel treatment for Hemophilia; Medication can be given up to once every 2 months
Qfitlia does not replace the missing clotting factor. Rather, it reduces the amount of a protein called antithrombin, leading ...
GEN - Genetic Engineering and Biotechnology News10h
RNAi Therapeutic for Hemophilia A or B Gets FDA Approval
Qfitlia (fitusiran), an siRNA drug to treat the frequency of bleeding episodes in adult and pediatric patients with hemophilia A or B, gets FDA approval.
BioPharma Dive3d
FDA approves first-of-its-kind RNA drug for hemophilia
The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare ...
Technology Networks1d
FDA Approves Novel Treatment for Hemophilia A or B
The FDA has approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in ...
360Dx10h
Siemens Healthineers Gains FDA 510(k) Clearance for Blood Clot Drug CDx
The firm's Innovance Antithrombin assay is used to monitor antithrombin activity levels in hemophilia patients and aid dosing decisions for a routine prophylaxis.
Fierce Pharma3d
Sanofi's versatile Qfitlia scores FDA nod to enter crowded hemophilia market
Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last three years, the FDA has approved six new drugs for hemophilia. And now the U.
The Joplin Globe3d
Antithrombin Blood Test from Siemens Healthineers Now FDA Cleared as a Companion Diagnostic for Qfitlia, a Sanofi Hemophilia Therapy
Siemens Healthineers announced today its Innovance Antithrombin assay has achieved FDA clearance for a new claim allowing it ...
Yahoo Finance3d
FDA Approves Novel Treatment for Hemophilia A or B, with or without Factor Inhibitors
Hemophilia A and hemophilia B are genetic bleeding disorders caused by a dysfunction or deficiency of coagulation factor VIII (FVIII) or IX (FIX), respectively. Patients with these hemophilias are ...
FDA Approves Novel Treatment for Hemophilia A or B, with or without Factor Inhibitors
Today, the U.S. Food and Drug Administration approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of ...